Genesis Therapeutics

Principal Software Engineer - Computational Chemistry / Molecular Dynamics

New York, New York, United States

Genesis Therapeutics Logo
Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, Artificial IntelligenceIndustries

Requirements

Candidates should possess a Bachelor's degree in a relevant scientific field, such as Chemistry, Physics, or Computer Science, and have a strong background in computational chemistry and molecular dynamics. Experience with developing and maintaining complex computational workflows is essential, along with the ability to provide technical and scientific insights into software architecture. Candidates should be comfortable working across all levels of the software stack, building intuitive APIs and libraries, and have experience writing production code and driving projects to completion.

Responsibilities

The Principal Software Engineer will build and maintain complex computational chemistry workflows for drug discovery, working closely with computational chemists and CADD scientists to productionize new computational methods for molecular property prediction. They will also contribute to scaling the data infrastructure to handle large datasets and parallel simulations, leading, mentoring, and coaching engineers from diverse backgrounds. Furthermore, they will monitor and interpret changes in employment legislation across North America and develop HR policies to ensure compliance, as well as advise management on HR-related risk mitigation strategies.

Skills

Computational Chemistry
Drug Discovery
Machine Learning
Biophysical Simulation
Software Development
API Development
Workflow Automation
Data Infrastructure
Parallel Computing
Mentoring
Project Leadership

Genesis Therapeutics

AI-driven drug discovery for pharmaceuticals

About Genesis Therapeutics

Genesis Therapeutics accelerates the development of new medicines by using artificial intelligence in drug discovery. The company combines 3D spatial graph modeling and molecular simulation to identify potential drug candidates and explore new chemical spaces. Unlike its competitors, Genesis Therapeutics focuses on strategic partnerships with other biotech and pharmaceutical companies, generating revenue through upfront payments and future earnings based on drug success. The goal is to transform the drug discovery process and bring new therapies to market.

Key Metrics

Burlingame, CaliforniaHeadquarters
2019Year Founded
$272.5MTotal Funding
SERIES_BCompany Stage
AI & Machine Learning, BiotechnologyIndustries
51-200Employees

Benefits

Competitive salary
Equity
Medical, dental, & vision insurance
401(k) program

Risks

Competition from AI-driven companies like Insilico Medicine and Exscientia is increasing.
Over-reliance on partnerships could lead to financial instability if drugs aren't successful.
Rapid AI advancements may render current models like GEMS obsolete without updates.

Differentiation

Genesis Therapeutics uses AI to accelerate drug discovery with 3D spatial graph modeling.
The GEMS platform integrates deep learning, molecular simulations, and generative AI for drug design.
Strategic partnerships with Eli Lilly and Gilead highlight Genesis' industry collaboration strength.

Upsides

Partnership with NVIDIA enhances GEMS platform for targeting undruggable diseases.
$224 million equity investment boosts research and development capabilities.
Recognition as a 'Fierce 15' company underscores AI's role in breakthrough therapeutics.

Land your dream remote job 3x faster with AI